Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity and safety study of Synflorix pneumococcal vaccine in children at increased risk of pneumococcal infection has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections
• Streptococcal Infections

Drugs mentioned

• Synflorix (10-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal, Streptococcus Pneumoniae Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2017-01-09